Mednet Logo
HomeNeurology
Neurology

Neurology

Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.

Recent Discussions

Should aTTR mutation with bilateral carpal tunnel alone prompt treatment with a gene silencing drug?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Cedars-Sinai Medical Center

Carpal Tunnel Syndrome does not qualify as a peripheral neuropathy due to TTR amyloid. The amyloid deposition is in the soft and/or connective tissue and not in the nerve. As such, there is no clear indication to treat as much as one might be tempted. Careful follow-up and treatment as soon as neuro...

How would you empirically manage a large sellar/suprasellar mass with encasement of the right cavernous and terminal internal carotid arteries?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

Knowing the histology of the mass would really help in creating more accurate treatment recommendations. A biopsy of a sellar mass is usually accomplished by an endonasal-endoscopic trans-sphenoidal approach utilizing the expertise of an ENT surgeon and a skull-base neurosurgeon. However, in this ca...

How do you counsel patients and caregivers about the trajectory of cognitive decline in Parkinson’s disease?

1
2 Answers

Mednet Member
Mednet Member
Neurology · Keck School of Medicine of USC

I address the subject of cognitive impairment fairly early in PD, since patients may notice mild deficits in multitasking and attention even within the first few years of diagnosis. Strategies such as making lists and breaking down individual tasks are effective in preserving independence. Worsening...

For a patient with acute stroke who cannot tolerate statins, what is your preferred second-line agent for secondary prevention?

1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Northwestern Memorial Hospital

First question - is the patient experiencing the nocebo effect? I would explore statin-based symptoms. Ezetimibe - if only needs a small reduction. If you need to be more aggressive, I would use PCSK9 inhibitors. If the patient cannot tolerate a PCSK9 inhibitor or if you need more lowering, you can ...

How do you treat nocturnal leg cramps?

5
8 Answers

Mednet Member
Mednet Member
Neurology · VUMC Neurology

Nocturnal leg cramps are similar to daytime leg cramps, but stretching may be less convenient to use as a remedy, as sleep can be further disrupted. Treating and preventing leg cramps typically utilizes some combination of hydration and electrolytes but sometimes, medications can help. Consider the ...

What are your preferred second-line medications for trigeminal neuralgia?

1
4 Answers

Mednet Member
Mednet Member
Neurology · UPMC

My first line is oxcarbazepine or carbamazepine. The second line is gabapentin. Then, in no particular order, baclofen and lamotrigine. Other options to try: pimozide, tizanidine, phenytoin, valproic acid. If 1 agent does not provide good control, I refer to a surgeon as we try a 2nd agent.

At what lab values (ferritin, TSAT%) would you offer IV iron therapy to patients with restless leg syndrome?

3
2 Answers

Mednet Member
Mednet Member
Hematology · Georgetown University School of Medicine

1. I am hopeful that practitioners will start understanding that ferritin alone is not enough to assess iron because of its acute phase reactivity. I like to order iron parameters after a 5-9 hour fast so the serum iron is not speciously elevated and get a ferritin and TSAT. If the ferritin is <30 a...

What clinical features predict visual recovery from optic neuritis in NMOSD?

1 Answers

Mednet Member
Mednet Member
Neurology · Mayo

The main clinical feature associated with outcomes is the severity of vision loss at nadir. The more severe the vision loss, the higher the risk of poor outcomes. However, there can be patients with very severe vision loss (no light perception) who can still recover to 20/20. The correlation with ra...

What are your ACTRIMS 2026 top takeaways?

1 Answers

Mednet Member
Mednet Member
Neurology · University of Ottawa

1. Abstract and presentation CE2.2 from Dr. Dalia Rotstein in Toronto (Rotstein et al., ACTRIMS 2026). With so much press on the role of EBV in MS and data strongly suggesting that exposure is nearly an absolute requirement for having the disease, some people were actually advocating testing a patie...

How does progression independent of relapse activity (PIRMA) influence your decision to change treatment in relapsing remitting multiple sclerosis?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Cleveland Clinic

In a patient who is progressing in the absence of relapse activity, I typically do not change DMT and instead focus on managing the symptoms directly. Such as physical therapy or walking aids, physical worsening, cognitive rehab, OT for fatigue issues, or counseling if mood issues are contributing t...